NovaBay Pharma (NBY) Reports In-Line Q4 EPS, Revenues Miss
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
NovaBay Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results
March 25, 2021 4:05 PM EDTAvenova® unit sales set record for second consecutive quarter Net product revenue increased 51% for 2020 Exited 2020 with $12.0 million in cash and equivalents Avenova access expanded to CVS stores and CVS online
Conference call begins at 4:30 p.m. Eastern time today
EMERYVILLE, Calif.--(BUSINESS... More